Innovation in Immuno-Oncology: Breaking Down the Barriers

Date: Wednesday, August 14th, 2019
Time: 8:00 am - 4:30 pm EST
Location: Dante Alighieri Society of Massachusetts, 41 Hampshire Street, Cambridge, MA, 02139

Join us for a day of transformative research with implications for drug discovery and clinical practice shutterstock_313800779_Greenacross the field of immuno-oncology in the heart of Cambridge, MA at the Dante Alighieri Society of Massachusetts. Come listen to your colleagues in pharma, biotech and academia discuss how their research is breaking down the barriers to novel oncology treatment options.

Register now to hold your spot for our complimentary event! Limited space available.

Speakers from various organizations including:

  • Parul Agnihotri, PhD, Genocea Biosciences
  • Lorella Di Donato, PhD, Caprion Biosciences
  • Johanna K. Kaufmann, PhD, TESARO a GSK Company
  • Shashi Murthy, PhD, Flaskworks
  • Julia Schüler, PhD, DVM, Charles River Laboratories
  • Russel Weiner, PhD, the Bill & Melinda Gates Medical Research Institute


8:00 - 8:30 am  Registration and breakfast
8:30 – 9:00 am Welcome and Introductions
Cathie G. Miller, PhD, Director of Product Marketing, Personalized Medicine, BioIVT
9:00 – 10:00 am Innovative Approaches for Neoantigen-Based T Cell Therapy Manufacturing
Shashi Murthy, PhD, Founder & CTO, Flaskworks
10:00 – 11:00 am PDX Models of Solid Cancer Express Distinct Cytokine Profiles Relating to
Their Tumor Infiltrating Lymphocyte Landscape

Julia Schüler, PhD, DVM, Research Director, Charles River Labs
11:00 am – 12:00 pm A GCLP Workflow for the Measurement of Protein Biomarkers in FFPE Tissue Samples by Mass Spectrometry
Lorella Di Donato, PhD, Senior Vice-President and Chief Operating Officer, Caprion Biosciences
12:00 – 1:00 pm Lunch 
1:00 – 2:00 pm Beyond PD-1 Blockade: Combination Immune Checkpoint Inhibition Engages Multiple Mechanisms of Action
Johanna K. Kaufmann, PhD, Associate Director, Immuno-Oncology, Tesaro, a GSK Company
2:00 – 2:15 pm Break, Coffee and refreshments will be served
2:15 – 3:15 pm ATLAS™ Technology Improves Neoantigen Selection for Personalized Cancer Vaccines
Parul Agnihotri, PhD, Scientist I, Translational Immunology, Genocea Biosciences
3:15 – 4:15 pm

Successful Implementation of Global Biomarker Strategies:
Pre-Analytics Matters (But is Often Ignored)
Russel Weiner, PhD, Head, Bioanalysis And Biomarker Development The Bill & Melinda Gates Medical Research Institute

4:15 – 4:30 pm Closing Remarks
Cathie G. Miller, PhD, Director of Product Marketing, Personalized Medicine, BioIVT


Register Now